Re-Launch 3-MT RIA

It’s with pleasure to inform you that the revision > of the 3-MT-RIA (catalogue no. BA R-8800)< is finished and that this assay is available again effective immediately.

This is the FIRST COMMERCIAL IMMUNOASSAY WORLDWIDE for the quantitative determination of

 

3-Methoxytyramine (3-MT)

in human plasma.

BACKGROUND:

The determination of normetanephrine and metanephrine in plasma is a sensitive test for diagnosing phaechromocytoma and paragangliomas (PPGLs) – but it does not provide the possibility to detect dopamine-producing tumours. Dopamine and especially its O-methylated metabolite 3-MT are reliable biomarkers for the detection of malignant PPGLs.

The assay compares with excellence to the LC-MS/MS method (please refer to the flyer attached) and offers an accurate, selective and sensitive measurement of 3-MT.

The assay itself uses an elegant extraction procedure followed by a competitive RIA (please refer to the instructions for use in the attachment).

 

With this assay LDN is now able to offer the most comprehensive panel worldwide for the measurement of PPGL/Pheochromocytoma-relevant parameters including the assays for:

  • Urinary Metanephrine/Normetanephrine (free and total; ELISA & RIA)
  • Plasma Metanephrine/Normetanephrine (ELISA & RIA)
  • Catecholamines in plasma and urine (ELISA & RIA)
  • Chromogranin A (ELISA)
  • and – closing the diagnostic gap – 3-Methoxytyramine (RIA)
0

Start typing and press Enter to search